Cheaper drug challenge: can methotrexate match expensive treatment for dangerous blood vessel disease?
NCT ID NCT03892785
Summary
This study compares two drugs, methotrexate and tocilizumab, to control giant cell arteritis—a serious inflammatory blood vessel disease that can cause vision loss. Both aim to keep the disease in remission while reducing patients' need for long-term steroid treatments, which often cause severe side effects. The trial will see if the less expensive methotrexate works as well as tocilizumab over 18 months in 230 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079, France
Conditions
Explore the condition pages connected to this study.